BCRP在浸润性乳腺癌中的表达及其与上皮间质转化相关蛋白的相关性
Expression of BCRP in invasive breast cancer,and its correlation with the epithelial-mesenchymal transition-related protein
-
摘要: 目的:探讨乳腺癌耐药蛋白(BCRP)在浸润性乳腺癌组织中的表达情况及其与上皮间质转化相关蛋白的相关性。方法:采用免疫组织化学方法检测80例浸润性乳腺癌组织、40例癌旁组织、40例乳腺纤维腺瘤组织中BCRP蛋白的表达情况,分析其与临床病理参数的关系,进一步研究BCRP蛋白与上皮性钙黏蛋白、神经性钙黏蛋白的相关性。结果:BCRP蛋白在浸润性乳腺癌中的阳性表达率为57.5%。BCRP蛋白阳性表达率在组织学分级、淋巴结转移和TNM分期间差异均有统计学意义(P<0.05~P<0.01)。BCRP与HER-2、神经性钙黏蛋白表达均呈正相关关系(P<0.01),与上皮性钙黏蛋白呈负相关关系(P<0.01)。结论:在浸润性乳腺癌中,BCRP蛋白可能与乳腺癌的发生、发展密切有关,同时与上皮间质转化存在一定的相关性。Abstract: Objective: To investigate the expression of breast cancer resistance protein(BCRP) in invasive breast cancer,and its correlation with the epithelial-mesenchymal transition-related protein.Methods: The expressions of BCRP in 80 invasive breast cancer tissue specimens,40 peritumoral tissue specimens and 40 breast fibroadenoma tissue specimens were detected using immunohistochemistry.The relationship between the expression of BCRP and clinical pathological parameters was analyzed,and the correlations of the expression of BCRP with E-cadhein and N-cadhein were investigated.Results: The positive expression rate of BCRP in invasive breast cancer tissue was 57.5%.The differences of the positive expression rate of BCRP in different histological grade,lymph node metastasis and TNM staging were not statistically significant(P<0.05 to P< 0.01).The expression rate of BCRP were positively and negatively with the expressions of HER-2 and N-cadherin,and E-cadherin,respectively(P<0.01).Conclusions: The BCRP may be involved in the occurrence and development in invasive breast cancer,and which is correlation with EMT.
-
[1] CAI J,TIAN AX,WANG QS,et al.FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal transition and multidrug resistance of basal-like breast cancer[J].Cancer Lett,2015,367(2):129. [2] NIER EL,ROCHA-SALES B,LAUAND C,et al.The multiple facets of drug resistance:one history,different approaches[J].J Exp Clin Cancer Res 2014,2014,33(1):37. [3] GOIDHIRSCH A,WOOD WC.Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J].Ann Oncol,2011,22(8):1736. [4] MO W,ZHANG JT.Human ABCG2:structure,function,and its role in multidrug resistance[J].Int J Biochem Mol Biol,2012,3(1):1. [5] STACY AE,JANSSON PJ,RICHARDSON DR.Molecular pharmacology of ABCG2 and its role in chemoresistance[J].Mol Pharmacol,2013,84(5):655. [6] 王兴,姜真,孙长岗.乙醛脱氢酶1与乳腺癌耐药蛋白在乳腺癌中的表达及相关性研究[J].中国癌症杂志,2014,24(3):175. [7] 梁茱,付生苗.乳腺癌耐药基因的研究进展和临床应用[J].中国热带医学,2011,11(4):511. [8] XIANG L,SU P,XIA SJ,et al.ABCG2 is associated with HER-2 expression,lymph node metastasis and clinical stage in breast invasive ductal carcinoma[J].Diagn Pathol,2011,6:90. [9] BARANWAL S,ALAHARI SK.Molecular mechanisms controlling E-cadherin expression in breast cancer[J].Biochem Biophys Res Commun,2009,384(1):6. [10] ZHANG JC,LIANG Q,LEI Y,et al.SOX4 induces epithelial-mesenchymal transition and contributes to Breast Cancer progression[J].Cancer Research,2012,72(17):4597. [11] NAKANISHI T,ROSS DD.Breast cancer resistance protein(BCRP/ABCG2):its role in multidrug resistance and regulation of its gene expression[J].Chin J Cancer,2012,31(2):73. [12] WESTOVER D,LI F.New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies[J].J Exp Clin Cancer Res,2015,34:159. [13] BONAVIDA B,BARITAKI S.The novel role of Yin Yang 1 in the regulation of epithelial to mesenchymal transition in cancer via the dysregulated NF-κB/Snail/YY1/RKIP/PTEN Circuitry[J].Crit Rev Oncog,2011,16(3/4):211. [14] 陈伟娟,王辉,唐勇,等.乳腺癌上皮-间质转化后引发BCRP介导的多药耐药的研究[J].癌症,2010,29(2):159. [15] EHATA S,JOHANSSON E,KATAYAMA R,et al.Transforming growth factor-β decreases the cancer-initiating cell population within diffuse-type gastric carcinoma cells[J].Oncogene,2011,30(14):1693. [16] WANG Y,ZHOU BP.Epithelial-mesenchymal transition in breast cancer progression and metastasis[J].Chin J Cancer,2011,30(9):603.
计量
- 文章访问数: 3686
- HTML全文浏览量: 457
- PDF下载量: 111
- 被引次数: 0